Overview Marqibo® Alocrest™ Brakiva™ Menadione Topical Lotion Hana Clinical Trials Publications Presentations Click here to watch the Mechanism of Action video		Alocrest™ (vinorelbine liposomes injection, OPTISOME™) A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity: A 47% disease control rate (1PR, 13 SD) across a broad range of doses in mostly heavily pretreated patients with relapsed and/or refractory solid tumors Maximum tolerated dose of 28 mg/m2in heavily pretreated patients that is comparable to that of un-encapsulated vinorelbine. Possibility to increase this dose level in future trials in non-heavily pretreated patients Reversible neutropenia without fever was the most common dose limiting toxicity No peripheral vein irritation Preclinical data demonstrate the value of Alocrest™ over standard vinorelbine (VRL): Prolonged circulation and 100-fold increased plasma area under concentration-time curve (AUC) 9.5-fold increased VRL exposure (tissue AUC) at tumor sites Up to a 3.5-fold increased therapeutic index in xenograft models Alocrest has the potential to deliver improved safety and efficacy compared to un-encapsulated vinorelbine injection in target populations as non-small cell lung cancer in the elderly. Ongoing Trials Phase I: Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Publications ESMO 2008 AACR NCI EORTC 2007 (injection results) AACR NCI EORTC 2007 (phase 1 and PK profile study) For further information on our product pipeline and/or business development inquiries please contact the Business Development Department.
© 2010 Hana Biosciences. Web design by Global 1 Design.